Related references
Note: Only part of the references are listed.Antibody–Drug Conjugate Payloads; Study of Auristatin Derivatives
Michinori Akaiwa et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2020)
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
Suparna Wedam et al.
CLINICAL CANCER RESEARCH (2020)
Chemical Modification of Linkers Provides Stable Linker-Payloads for the Generation of Antibody-Drug Conjugates
Yam B. Poudel et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Antibody-Drug Conjugates: The Last Decade
Nicolas Joubert et al.
PHARMACEUTICALS (2020)
Sulfatase-cleavable linkers for antibody-drug conjugates
Jonathan D. Bargh et al.
CHEMICAL SCIENCE (2020)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF-κB Inhibitory Capacity of Pyrrolobenzodiazepines (PBDs)
David B. Corcoran et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation
Nicholas C. Yoder et al.
MOLECULAR PHARMACEUTICS (2019)
Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
Min-Ho Park et al.
MOLECULES (2019)
New linker structures applied in glycosite-specific antibody drug conjugates
Faridoon et al.
ORGANIC CHEMISTRY FRONTIERS (2019)
Antibody Structure and Function: The Basis for Engineering Therapeutics
Mark L. Chiu et al.
ANTIBODIES (2019)
BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive breast cancer
W. Tang et al.
CANCER RESEARCH (2019)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
Ricarda M. Hoffmann et al.
ONCOIMMUNOLOGY (2018)
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies
Francesca Zammarchi et al.
BLOOD (2018)
A thioether-directed palladium-cleavable linker for targeted bioorthogonal drug decaging
Benjamin J. Stenton et al.
CHEMICAL SCIENCE (2018)
Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice
Yasuaki Anami et al.
NATURE COMMUNICATIONS (2018)
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia
Mohammed Gbadamosi et al.
FUTURE ONCOLOGY (2018)
HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma
Andreas Pahl et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Yelena Kovtun et al.
BLOOD ADVANCES (2018)
From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
Julia Mantaj et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates
Patrick J. Burke et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
Hao Chen et al.
MOLECULES (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Linkers Having a Crucial Role in Antibody-Drug Conjugates
Jun Lu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates
Jeffrey C. Kern et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
Processes for Constructing Homogeneous Antibody Drug Conjugates
David Y. Jackson
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2016)
Antibody-drug conjugates as novel anti-cancer chemotherapeutics
Christina Peters et al.
BIOSCIENCE REPORTS (2015)
Current methods for the synthesis of homogeneous antibody-drug conjugates
Alicja M. Sochaj et al.
BIOTECHNOLOGY ADVANCES (2015)
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus
Sophie M. Lehar et al.
NATURE (2015)
Current ADC Linker Chemistry
Nareshkumar Jain et al.
PHARMACEUTICAL RESEARCH (2015)
Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy
Ravi V. J. Chari et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Antibody-drug conjugates: current status and future directions
Heidi L. Perez et al.
DRUG DISCOVERY TODAY (2014)
Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
Sohita Dhillon
DRUGS (2014)
Site-specific antibody drug conjugates for cancer therapy
Siler Panowski et al.
MABS (2014)
Emerging classes of armed antibody therapeutics against cancer
Christian Hess et al.
MEDCHEMCOMM (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
Cathepsin B as a cancer target
Christopher S. Gondi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
GC-Targeted C8-Linked Pyrrolobenzodiazepine-Biaryl Conjugates with Femtomolar in Vitro Cytotoxicity and in Vivo Antitumor Activity in Mouse Models
Khondaker M. Rahman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer
Jonathan G. Drachman et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies
Ursula J. E. Seidel et al.
FRONTIERS IN IMMUNOLOGY (2013)
Brentuximab vedotin
Niels W. C. J. van de Donk et al.
MABS (2012)
Trastuzumab: updatedmechanisms of action and resistance in breast cancer
Thuy Vu et al.
FRONTIERS IN ONCOLOGY (2012)
Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
Stephen I. Rudnick et al.
CANCER RESEARCH (2011)
Investigational antibody-drug conjugates for hematological malignancies
Andrew G. Polson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates
Robert Y. Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Observation of the reversibility of a covalent pyrrolobenzodiazepine (PBD) DNA adduct by HPLC/MS and CD spectroscopy
Khondaker M. Rahman et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2011)
Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells
Victor S. Goldmacher et al.
THERAPEUTIC DELIVERY (2011)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
The Pyrrolobenzodiazepine Dimer SJG-136 Forms Sequence-Dependent Intrastrand DNA Cross-Links and Monoalkylated Adducts in Addition to Interstrand Cross-Links
Khondaker M. Rahman et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Cell killing by antibody-drug conjugates
Yelena V. Kovtun et al.
CANCER LETTERS (2007)
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange
Marijn van der Neut Kolfschoten et al.
SCIENCE (2007)
Antibody therapeutics: isotype and glycoform selection
Roy Jefferis
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
HK Erickson et al.
CANCER RESEARCH (2006)
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
YV Kovtun et al.
CANCER RESEARCH (2006)
Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resources
NS Lipman et al.
ILAR JOURNAL (2005)
Glutathione metabolism and its implications for health
GY Wu et al.
JOURNAL OF NUTRITION (2004)
Complement function in mAb-mediated cancer immunotherapy
KA Gelderman et al.
TRENDS IN IMMUNOLOGY (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
OH Brekke et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Differences in CD33 intensity between various myeloid neoplasms
I Jilani et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2002)
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
GM Dubowchik et al.
BIOCONJUGATE CHEMISTRY (2002)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
CC-1065 and the duocarmycins: recent developments
B Cacciari et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2000)
Share Paper
